A 48-year-old woman with type 1 diabetes mellitus for 15 years and poor glycemic control (HbA1c 10.5%) presents with sudden onset of floaters and blurred vision in the right eye for 2 days. On examination, visual acuity is 6/60 in the right eye. Dilated fundoscopy reveals extensive vitreous hemorrhage obscuring the posterior pole. B-scan ultrasonography shows no retinal detachment. What is the most appropriate immediate management?

Explanation

## Management of Vitreous Hemorrhage in Diabetic Retinopathy **Key Point:** Vitreous hemorrhage (VH) in diabetic retinopathy is managed conservatively initially with anti-VEGF therapy, unless there is evidence of tractional retinal detachment, dense hemorrhage with poor view, or failure to clear within 3 months. ## Decision Algorithm for Diabetic VH ```mermaid flowchart TD A[Vitreous Hemorrhage in DR]:::outcome --> B{Retinal Detachment?}:::decision B -->|Yes| C[Urgent Vitrectomy]:::urgent B -->|No| D{Dense hemorrhage + poor view?}:::decision D -->|Yes, early intervention needed| E[Consider anti-VEGF or early vitrectomy]:::action D -->|No, can observe| F[Anti-VEGF injection]:::action F --> G[Observe 3 months]:::action G --> H{Hemorrhage cleared?}:::decision H -->|Yes| I[Continue monitoring]:::outcome H -->|No| J[Pars plana vitrectomy]:::action ``` ## Why Anti-VEGF Is First-Line for Uncomplicated VH 1. **Reduces neovascularization** — decreases ongoing bleeding and promotes hemorrhage resorption 2. **Non-invasive** — avoids surgical risks in a patient with poor glycemic control (higher infection/healing risk) 3. **Evidence-based** — multiple RCTs (e.g., DRCR.net Protocol S) show anti-VEGF (bevacizumab, aflibercept, ranibizumab) accelerates VH clearance 4. **Allows time for spontaneous clearance** — VH often resolves within 3 months with good glycemic control **High-Yield:** Anti-VEGF is particularly beneficial in proliferative DR with VH because it reduces neovascular activity, decreasing the risk of recurrent hemorrhage and tractional detachment. ## When to Proceed Directly to Vitrectomy | Indication | Rationale | |-----------|----------| | Tractional or rhegmatogenous RD | Anatomic emergency; requires surgical repair | | Dense, persistent VH (>3 months) with poor visual potential | Prevents vision recovery | | Rubeotic glaucoma secondary to VH | Requires visualization for PRP or anti-VEGF | | Vitreous infection (endophthalmitis) | Requires vitreous sampling and antibiotics | **Clinical Pearl:** This patient has no retinal detachment on B-scan and is only 2 days into symptoms—too early for vitrectomy. Anti-VEGF injection followed by observation is the evidence-based approach. **Mnemonic for VH management:** **"BRAVE"** - **B**evacizumab/anti-VEGF first - **R**etinal detachment? → urgent vitrectomy - **A**void immediate surgery if no RD - **V**itrectomy at 3 months if no clearance - **E**nsure glycemic control throughout